Age and outcome after acute coronary syndromes without persistent ST- segment elevation

American Heart Journal

Volumn 139, Issue 5, 2000, Pages 858-866

  Hasdai, David ^a   Holmes Jr , David R ^b   Criger, Douglas A ^c   Topol, Eric J ^c   Califf, Robert M ^c   Harrington, Robert A ^c  

^a RABIN MEDICAL CENTER   (Israel)

^b MAYO CLINIC   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR; PLACEBO;

ADULT; AGE; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HEART MUSCLE ISCHEMIA; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

EID: 0034027115     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(00)90018-8     Document Type: Article

References (16)

1. 1. The GUSTO IIb investigators. A comparison of recombinant hirudin versus heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-82.
2. 2. Gunnar RM, Bourdillon PDV, Dixon DW, et al. Guidelines for early management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Procedures. J Am Coll Cardiol 1990;16:249-92.
3. 3. Hamm CW, Goldmann BU, Heeschen C, et al. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 1997;337: 1648-53.
4. 4. Hasdai D, Berger PB, Bell MR, et al. The changing face of coronary interventional practice: The Mayo Clinic experience. Arch Intern Med 1997;157:677-82.
5. 5. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-23.
6. 6. Reynen K, Bachman K. Coronary arteriography in elderly patients: risk, therapeutic consequences and long-term follow-up. Coron Artery Dis 1997;8:657-66.
7. 7. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41021 patients. Circulation 1995;91:1659-68.
8. 8. The PURSUIT investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation: a randomized, placebo-controlled, clinical trial. N Engl J Med 1998;339:436-43.
9. 9. Krantz D, Hecht A, Fuhrmann I. The influence of age on the wound healing of experimental myocardial infarction in rats. Exp Pathol 1975;11:107-14.
10. 10. Bayer AJ, Chadha JS, Farag RR, et al. Changing presentation of myocardial infarction with increasing old age. J Am Geriatr Soc 1986;34:263-6.
11. 11. Pilote L, Miller DP, Califf RM, et al. Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. N Engl J Med 1996;335:1198-205.
12. 12. Calvin JE, Klein LW, VandenBerg BJ, et al. Clinical predictors easily obtained at presentation predict resource utilization in unstable angina. Am Heart J 1998;136:378-81.
13. 13. Yusuf S, Flather M, Pogue J, et al. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. Lancet 1998;352:507-14.
14. 14. Malane ML, Rosen LB, Goodwin JS. Complications of acute myocardial infarction in patients ≥90 years of age. Am J Cardiol 1998;81:638-41.
15. 15. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
16. 16. Yusuf S, Wittes J, Probsfield J, et al. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991;266:93-8.